XOMA (XOMA)
(Delayed Data from NSDQ)
$24.05 USD
+0.71 (3.04%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $23.81 -0.24 (-1.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
XOMA Corporation [XOMA]
Reports for Purchase
Showing records 1 - 20 ( 327 total )
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Creativity in Value Creation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Another Right Place, Right Time Transaction; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Our XOMA All Grown Up; Big Win for Cash Balance and Business Model; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for XOMA 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
3Q23 Results; Diverse Pipeline Supported by Growing Revenue; Shopping Continues; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Third Vabysmo Approval, A Day One Check, and A Strategic Move; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Third Indication For Vabysmo Seems Not Too Far Off; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Vabysmo Royalty Cash Flow Pushing Forward Nicely; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
2Q23 Results; Inbounds at Highest Levels as Royalties Grow; Target Upped to $74
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Near-Term Potential Royalty Addition Continues to Highlight Aggregation Model; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
IXINITY Reach Should Broaden and Hit XOMA''s Bottom Line; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
New Partner, More Royalties; Hematology Portfolio Expands With the Addition of IXINITY
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
2022 Results; Business Model Begins to Bear Fruit With Recent Asset Approval and Acquisition
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Check a Nice One Off the Shopping List; Organon to Drive Clinical Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
3Q22 Results; Royalties Start Flowing and Shopping Continues; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Sustained Revenue Line Taking Real Form; Faricimab Market Expands Into Europe
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
2Q22 Results; Partnered Assets Continue to Make Headway as Asset Portfolio Matures
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
1Q22 Results; All RIZE for Positive Phase 2b Readout in CHI from Partnered Asset
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
All RIZE for Positive Phase 2b Readout in CHI from XOMA Partnered Asset
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
RZ358 Continues to Advance; Positive Clinical Update From Partnered Asset With Data Presentation Expected 1H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J